Jiang Chonghua, Zhang Hao, Wu Wantao, Wang Zeyu, Dai Ziyu, Zhang Liyang, Liu Zhixiong, Cheng Quan
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Front Cell Dev Biol. 2022 Feb 2;9:760929. doi: 10.3389/fcell.2021.760929. eCollection 2021.
The prognosis of gliomas is poor and there are limited therapeutic approaches. Immunotherapy has become a promising treatment for gliomas. Here, we explored the expression pattern of Lck/yes-related protein tyrosine kinase (LYN) in gliomas and assessed its value as an immunotherapy biomarker. Transcriptional data was mined from two publicly available datasets, TCGA and CGGA, and used to investigate the correlation between LYN and clinical characteristics including patient prognosis, somatic mutation, and immune infiltrating features in gliomas. Besides, the correlation between LYN and classical immune checkpoint molecules was explored. Glioma samples obtained from the Xiangya Hospital cohort were used for immunohistochemistry staining. High expression level of LYN was observed in advanced gliomas and other cancer types, which predicted a worse prognosis. LYN stratified patients' survival in the Xiangya cohort and was also significantly associated with infiltrating immune cell types and inflammatory activities in the tumor microenvironment. LYN was involved in tumor mutation, correlated with the regulation of oncogenic genes, and also showed a significant positive correlation with PD-L1. LYN can be a potential diagnostic marker and immunotherapy marker in gliomas.
胶质瘤的预后较差，治疗方法有限。免疫疗法已成为治疗胶质瘤的一种有前景的方法。在此，我们探究了淋巴细胞特异性蛋白酪氨酸激酶（LYN）在胶质瘤中的表达模式，并评估了其作为免疫治疗生物标志物的价值。从两个公开可用的数据集TCGA和CGGA中挖掘转录数据，用于研究LYN与胶质瘤患者预后、体细胞突变和免疫浸润特征等临床特征之间的相关性。此外，还探究了LYN与经典免疫检查点分子之间的相关性。从湘雅医院队列中获取的胶质瘤样本用于免疫组织化学染色。在高级别胶质瘤和其他癌症类型中观察到LYN的高表达水平，这预示着更差的预后。LYN对湘雅队列中的患者生存进行了分层，并且还与肿瘤微环境中的免疫浸润细胞类型和炎症活动显著相关。LYN参与肿瘤突变，与致癌基因的调控相关，并且还与程序性死亡受体配体1（PD-L1）呈显著正相关。LYN可能是胶质瘤的一种潜在诊断标志物和免疫治疗标志物。
